Syngene International Limited

BSE:539268 Stock Report

Market Cap: ₹348.8b

Syngene International Valuation

Is 539268 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 539268 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 539268 (₹869.4) is trading above our estimate of fair value (₹132.15)

Significantly Below Fair Value: 539268 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 539268?

Key metric: As 539268 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 539268. This is calculated by dividing 539268's market cap by their current earnings.
What is 539268's PE Ratio?
PE Ratio72.4x
Earnings₹4.82b
Market Cap₹348.83b

Price to Earnings Ratio vs Peers

How does 539268's PE Ratio compare to its peers?

The above table shows the PE ratio for 539268 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average53.3x
INDGN Indegene
41.1x18.4%₹153.2b
AKUMS Akums Drugs and Pharmaceuticals
36.3xn/a₹100.7b
DIVISLAB Divi's Laboratories
86.7x23.7%₹1.6t
INNOVACAP Innova Captab
49.1x29.7%₹58.1b
539268 Syngene International
72.4x19.3%₹348.8b

Price-To-Earnings vs Peers: 539268 is expensive based on its Price-To-Earnings Ratio (72.4x) compared to the peer average (53.3x).

Price to Earnings Ratio vs Industry

How does 539268's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
539268 72.4xIndustry Avg. 31.4xNo. of Companies7PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 539268 is expensive based on its Price-To-Earnings Ratio (72.4x) compared to the Asian Life Sciences industry average (31.9x).

Price to Earnings Ratio vs Fair Ratio

What is 539268's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

539268 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio72.4x
Fair PE Ratio42.8x

Price-To-Earnings vs Fair Ratio: 539268 is expensive based on its Price-To-Earnings Ratio (72.4x) compared to the estimated Fair Price-To-Earnings Ratio (42.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 539268 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹869.40
₹862.50
-0.8%
14.9%₹1,030.00₹700.00n/a8
Nov ’25₹862.60
₹862.50
-0.01%
14.9%₹1,030.00₹700.00n/a8
Oct ’25₹909.60
₹760.63
-16.4%
13.0%₹925.00₹640.00n/a8
Sep ’25₹869.40
₹760.63
-12.5%
13.0%₹925.00₹640.00n/a8
Aug ’25₹829.25
₹766.22
-7.6%
12.4%₹925.00₹640.00n/a9
Jul ’25₹716.05
₹735.67
+2.7%
10.7%₹825.00₹620.00n/a9
Jun ’25₹672.30
₹735.67
+9.4%
10.7%₹825.00₹620.00n/a9
May ’25₹688.95
₹725.13
+5.3%
10.6%₹825.00₹620.00n/a8
Apr ’25₹707.95
₹745.14
+5.3%
7.3%₹811.00₹680.00n/a7
Mar ’25₹705.05
₹748.71
+6.2%
6.8%₹811.00₹680.00n/a7
Feb ’25₹745.70
₹750.14
+0.6%
7.0%₹811.00₹680.00n/a7
Jan ’25₹709.65
₹788.71
+11.1%
5.8%₹875.00₹731.00n/a7
Dec ’24₹746.45
₹782.63
+4.8%
5.8%₹875.00₹731.00n/a8
Nov ’24₹679.85
₹782.63
+15.1%
5.8%₹875.00₹731.00₹862.608
Oct ’24₹802.95
₹825.13
+2.8%
9.0%₹960.00₹740.00₹909.608
Sep ’24₹778.00
₹825.13
+6.1%
9.0%₹960.00₹740.00₹869.408
Aug ’24₹806.15
₹825.13
+2.4%
9.0%₹960.00₹740.00₹829.258
Jul ’24₹765.10
₹741.57
-3.1%
4.2%₹780.00₹695.00₹716.057
Jun ’24₹726.65
₹743.88
+2.4%
4.0%₹780.00₹695.00₹672.308
May ’24₹677.35
₹734.00
+8.4%
4.1%₹780.00₹695.00₹688.958
Apr ’24₹594.55
₹705.88
+18.7%
8.5%₹780.00₹610.00₹707.958
Mar ’24₹586.75
₹705.88
+20.3%
8.5%₹780.00₹610.00₹705.058
Feb ’24₹567.35
₹705.88
+24.4%
8.5%₹780.00₹610.00₹745.708
Jan ’24₹585.35
₹708.13
+21.0%
8.4%₹780.00₹590.00₹709.658
Dec ’23₹608.00
₹708.13
+16.5%
8.4%₹780.00₹590.00₹746.458
Nov ’23₹627.95
₹708.13
+12.8%
8.4%₹780.00₹590.00₹679.858

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Bal Pharma

₹2.1b

Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.

BALPHARMA

₹137.15

7D

13.8%

1Y

30.6%

Vivimed Labs

₹410.4m

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.

VIVIMEDLAB

₹4.95

7D

0%

1Y

-45.9%

Novartis India

₹25.3b

Operates as a healthcare company in India.

500672

₹1,025.80

7D

-3.4%

1Y

47.0%